Op2Lysis

Congrès français d'hémostase 2024 à Lille. Une session hémorragie cérébrale sera l'occasion de présenter les avancées dans la modélisation de cette pathologie pour proposer de nouveaux traitements à ce besoin médical non satisfait! #cfh2024

🇺🇸 🇬🇧 Successful first toxicology study 🩸🧠   💥We are delighted to announce that the O2L-001 technology developed by Op2Lysis to treat massive and deep cerebral haemorrhage has reached a new milestone. The first "Dose Range Finding" safety study has produced very positive results. This success means that highly effective doses can be used in clinical trials.   PR available on our website : https://lnkd.in/eY8vjSGE -------------- 🇫🇷 Première étude toxicologique positive 🩸🧠   💥Nous avons le plaisir d'annoncer que la technologie O2L-001 développée par Op2Lysis pour traiter les hémorragies cérébrales massives et profondes vient de franchir un nouveau palier. La première étude de sécurité « Dose Range Finding" a donné des résultats très positifs. Ce succès permet de mieux envisager des doses très efficaces en essai clinique.

🇺🇸 🇬🇧 Successful first toxicology study 🩸🧠   💥We are delighted to announce that the O2L-001 technology developed by Op2Lysis to treat massive and deep cerebral haemorrhage has reached a new milestone. The first "Dose Range Finding" safety study has produced very positive results. This success means that highly effective doses can be used in clinical trials.   PR available on our website : https://lnkd.in/eY8vjSGE -------------- 🇫🇷 Première étude toxicologique positive 🩸🧠   💥Nous avons le plaisir d'annoncer que la technologie O2L-001 développée par Op2Lysis pour traiter les hémorragies cérébrales massives et profondes vient de franchir un nouveau palier. La première étude de sécurité « Dose Range Finding" a donné des résultats très positifs. Ce succès permet de mieux envisager des doses très efficaces en essai clinique.

A huge need to detect and control high blood pressure, and to offer solution to treat the consequences of uncontroled HBP such as intracerebral hemorrhage Stroke Association Stroke Alliance For Europe (SAFE) Agence de l'innovation en santé European Innovation Council and SMEs Executive Agency (EISMEA)

A huge need to detect and control high blood pressure, and to offer solution to treat the consequences of uncontroled HBP such as intracerebral hemorrhage Stroke Association Stroke Alliance For Europe (SAFE) Agence de l'innovation en santé European Innovation Council and SMEs Executive Agency (EISMEA)

EIC Accélérateur -> Evènement Lauréats/Investisseurs 🗓 Le 19 juin dernier, le PCN Conseil européen de l'innovation (EIC) (avec le support d'EuroQuity - Bpifrance, María Cristina Chumacero, Marc Ranchon, Valentin Marin & Gaspar Lacour-Couderc) a organisé la première édition des "EIC Accelerator France Laureates"! 🌐 L'idée de cet évènement est de créer une communauté des lauréats EIC Accélérateur en France. 🎙 Les lauréats récents sont invités à présenter leurs sociétés et leurs innovations pour faire naître de futures collaborations 🤝 💥 Une trentaine de lauréats ont répondu présent pour participer à cette première édition! Avatar Medical, BrainEver, EVerZom, FineHeart, Greenerwave, LATTICE MEDICAL, METAFORA Biosystems, Op2Lysis, PannTheraPi, Aurora Sterilisation, Qarnot, ErVimmune, EverDye, SPARTHA Medical, SYNOVANCE, HEPHAISTOS-Pharma, UPMEM, ION-X, Look Up Space, PEPTINOV, Qfluidics, ReST THERAPEUTICS & VSORA 🎇 Quitte à rassembler certaines des plus belles startups Deeptech de France, autant convier des investisseurs 💰 🙋♂️🙋♀️ Une trentaine dont Omnes Capital, Supernova Invest et Iron Hands Capital ont fait le déplacement pour venir les rencontrer et peut-être investir dans certains lauréats ! #HorizonEurope #EIC #deeptech Gorka Gorazureta | Gilles Le Cocguen | Christian Dubarry | Jérôme Billé | Carole Miranda

We have finally received the publication of our article in #BRAIN journal 📰. We are very proud of this publication and of the collective work that has gone into it 🤝. ⭐ BRAIN is a leading journal in the field of clinical neurology 🧠! Audrey Thiebaut Jérôme Parcq - Op2Lysis Christophe Gaudin Mélina Ianszen Estelle Louet, Ph.D Marie-Julie Guichard, PhD Daniel F Hanley #team #collaboration #neurology #cerebralhemorrhage

📢 Reducing Hematoma Size: Key to Improving Outcomes in Intracerebral Hemorrhage - Insights from the ENRICH Trial Currently, there is no approved therapeutic approach for spontaneous intracerebral haemorrhage (sICH). Surgical evacuation of the haematoma via conventional craniotomy is recommended solely as a life-saving measure. However, small studies suggest that minimally invasive surgery and endoscopic-guided haematoma removal is safe and could enable over 90% haematoma resorption. This prompted the Early Minimally Invasive Removal of Intracerebral Haemorrhage (ENRICH) trial, which evaluated the outcomes of minimally invasive surgery using the BrainPath device in comparison to guideline-based medical management alone. Results indicated that the median time from last known well to randomisation was less than 13 hours, with a median of 1.5 hours from randomisation to surgery. This overcame a previous trial hurdle of obtaining written consent quickly in this indication. Primary efficacy results showed a mean score of 0.458 on the utility-weighted modified Rankin (UW-mRS) scale at 180 days for the surgery group, compared to 0.374 for the control group, with a between-group difference of +0.084. Notably, the difference was −0.013 for patients with haemorrhage in the deep location and +0.127 for those with haemorrhage in the lobar location. As noted in the publication, “in a frequentist analysis using the [standard] modified Rankin Scale (mRS), no conclusions can be drawn from these results”. This suggests the trial's positive outcome was influenced by the chosen utility-weighted scale and the adaptation of the protocol to include 70% of lobar sICH cases. Regarding the efficacy of the surgery, the mean percentage reduction in haematoma volume from baseline to 24 hours was 73%, with a mean post-surgery volume of 14.9 ml. This reduction was less effective than the over 90% reported in earlier studies. 📌 Key points include that large trials in ICH are feasible and that patient inclusion within the first 24 hours is achievable. This trial also supports the strategy that reducing the size of the haematoma following sICH is crucial for promoting better outcomes, as already suggested by the MITIE and STICH programmes. The ENRICH trial demonstrated a functional benefit of minimally invasive surgery combined with guideline-based medical management at 180 days. Nevertheless, the effect is primarily driven by lobar and superficial haematomas. Lobar ICH constitutes less than 50% of all sICH cases. Finally, the utility-weighted modified Rankin scale (UW-mRS), although used in ischaemic stroke trials, lacks specific validation for intracerebral haemorrhage. ✅ Overall, ENRICH represents a promising advance in the field of cerebral haemorrhage and reinforces the consensus to reduce the size of the haematoma that has formed after the haemorrhage in order to improve clinical outcome. https://lnkd.in/eN6dqBQs

News from the European Stroke Organisation Conference 2024 https://lnkd.in/esEydzzt #strokeawarenessmonth #cerebralhemorrhage #orphan #opportunities

𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐢𝐧𝐭𝐫𝐚𝐜𝐞𝐫𝐞𝐛𝐫𝐚𝐥 𝐡𝐚𝐞𝐦𝐨𝐫𝐫𝐡𝐚𝐠𝐞: 𝐚𝐧 𝐮𝐫𝐠𝐞𝐧𝐭 𝐧𝐞𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐫𝐞𝐝𝐮𝐜𝐞 𝐭𝐡𝐞 𝐜𝐨𝐬𝐭 𝐨𝐟 𝐈𝐂𝐇   📰 💶 A recent study published in the European Stroke Journal highlights the staggering costs associated with Intracerebral Haemorrhage (ICH 🩸🧠) and the urgent need to find effective therapeutic solutions. The research, based on a comprehensive analysis of healthcare and economic data from a database of 1,000 patients treated between 2003 and 2013 in Finland, reveals alarming figures for the financial burden of ICH. 𝐓𝐡𝐞 𝐦𝐞𝐚𝐧 𝟏𝟐-𝐦𝐨𝐧𝐭𝐡 𝐝𝐢𝐫𝐞𝐜𝐭 𝐜𝐨𝐬𝐭 𝐰𝐚𝐬 €𝟒𝟗,𝟕𝟓𝟒 𝐩𝐞𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 (𝐫𝐞𝐠𝐚𝐫𝐝𝐥𝐞𝐬𝐬 𝐨𝐟 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐨𝐮𝐭𝐜𝐨𝐦𝐞), with >80% of costs associated with hospitalisation and rehabilitation 💶 🏥. Not taken into account in this study is that ICH is also associated with mortality (45% at 12 months) and a high-rate heavy disability (51% of the survivors at 12 months) resulting in substantial economic expenditure due to lost productivity. In addition, although recovery is faster in the first few weeks, it can continue for many months after ICH. Therefore, assessing the long-term costs would provide a more complete estimate of the total economic burden of ICH on society. The study highlights critical unmet medical needs in the management of ICH. Despite advances in medical care, treatment options remain limited, leaving patients and carers to grapple with the heavy physical, emotional and financial consequences of the disease. ⚠ 𝗧𝗵𝗲 𝘂𝗿𝗴𝗲𝗻𝗰𝘆 𝗼𝗳 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗰𝗮𝗻𝗻𝗼𝘁 𝗯𝗲 𝗼𝘃𝗲𝗿𝘀𝘁𝗮𝘁𝗲𝗱 🚑 💊. Indeed, Marika Smeds and her colleagues have smartly pointed out that "total costs were substantially lower for those with a favourable outcome than for those who were permanently disabled at 12 months highlighting the importance and effectiveness of investment in improving and maintaining functional capacity": - €58,852 for those with a favourable outcome - €81,553 for those who were permanently disabled at 12 months Significant savings could be made by healthcare systems with innovative, high-performance drugs, which is what Op2Lysis is proposing to develop for intracerebral haemorrhage. #UnmetMedicalNeed #EconomicImpact #burden #ICH #ESOC2024 Characteristics of the publication: -      Journal: European Stroke Journal (rank in the TOP 20% both in Clinical Neurology and in Peripheral Vascular Disease) -      https://lnkd.in/e2nsrrMd